Shift Bioscience
Kaiser Karim is a Senior Research Scientist specializing in Target Validation at Shift Bioscience since May 2025. Previously, Kaiser held the role of Senior Scientist at bit.bio from November 2019 to March 2025, leading high-throughput genetic screening in human iPSCs and identifying rare gene targets for different cell types. Kaiser also contributed to a proof-of-concept Perturb-seq screen in human iPSC-derived neurons and played a significant role in data collection for a $40M Series B fundraising round. Earlier in 2013, Kaiser served as a Laboratory Demonstrator at Monash University Malaysia, co-supervising undergraduate biochemistry students. Kaiser earned a PhD in Clinical Neurosciences from the University of Cambridge and holds a BSc and Honours Degree in Medical Bioscience from Monash University Malaysia, along with a Pre-University qualification from Sunway University.
This person is not in any teams
This person is not in any offices
Shift Bioscience
Shift Bioscience is unlocking safe rejuvenation with cell simulations. Cellular reprogramming is a powerful biological pathway that can reverse ageing and age-driven diseases in the dish but is not yet safe for clinical use. Our team based in Cambridge UK has pioneered the first high throughput, high accuracy ageing biomarker, which can be leveraged in AI-based cell simulations to identify drug targets for safe rejuvenation.